)

BioXcel Therapeutics (BTAI) investor relations material
BioXcel Therapeutics Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Study background and clinical need
Acute agitation in bipolar disorder and schizophrenia is a major burden, often leading to ED visits and hospitalization if not managed early.
No FDA-approved therapies currently exist for at-home agitation management in these populations.
IGALMI (dexmedetomidine sublingual film/BXCL501) is FDA-approved for institutional use; the SERENITY At-Home Phase III trial evaluated its safety and efficacy for self-administration at home, aiming for label expansion.
Study design and patient population
SERENITY At-Home was a double-blind, placebo-controlled, 12-week trial with 246 randomized patients and over 2,600 treated agitation episodes.
Included adults aged 18–75 with schizophrenia, schizoaffective, schizophreniform, or bipolar I/II disorder, stable on psychotropic regimens, and with recent agitation history.
Excluded those with serious or unstable medical illness, certain personality disorders, or recent substance use disorder.
Patients self-administered the film as needed, with or without a co-resident informant, and could use alternative coping strategies.
Patients or caregivers completed a modified CGI-S assessment two hours after dosing.
Safety and tolerability results
BXCL501 was well tolerated with no drug-related serious adverse events, falls, or syncopes reported.
No patients discontinued due to treatment-emergent adverse events in the BXCL501 arm.
Adverse event profile was consistent with prior institutional studies and the approved IGALMI label; most events were mild.
Most common side effects: somnolence (22% first dose, 14% all doses vs. 17%/8% placebo), oral paresthesia/hypoesthesia, dizziness, dry mouth; incidence did not increase with repeat dosing.
No new or unexpected safety signals emerged with repeated use.
Next BioXcel Therapeutics earnings date

Next BioXcel Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage